904 related articles for article (PubMed ID: 19249432)
1. N-acetylcysteine versus AScorbic acid for preventing contrast-Induced nephropathy in patients with renal insufficiency undergoing coronary angiography NASPI study-a prospective randomized controlled trial.
Jo SH; Koo BK; Park JS; Kang HJ; Kim YJ; Kim HL; Chae IH; Choi DJ; Sohn DW; Oh BH; Park YB; Choi YS; Kim HS
Am Heart J; 2009 Mar; 157(3):576-83. PubMed ID: 19249432
[TBL] [Abstract][Full Text] [Related]
2. Acetylcysteine in the prevention of contrast-induced nephropathy after coronary angiography.
Oldemeyer JB; Biddle WP; Wurdeman RL; Mooss AN; Cichowski E; Hilleman DE
Am Heart J; 2003 Dec; 146(6):E23. PubMed ID: 14661012
[TBL] [Abstract][Full Text] [Related]
3. Intravenous N-acetylcysteine plus high-dose hydration versus high-dose hydration and standard hydration for the prevention of contrast-induced nephropathy: CASIS--a multicenter prospective controlled trial.
Koc F; Ozdemir K; Kaya MG; Dogdu O; Vatankulu MA; Ayhan S; Erkorkmaz U; Sonmez O; Aygul MU; Kalay N; Kayrak M; Karabag T; Alihanoglu Y; Gunebakmaz O
Int J Cardiol; 2012 Mar; 155(3):418-23. PubMed ID: 21106264
[TBL] [Abstract][Full Text] [Related]
4. Reno-protective effect of N-acetyl cysteine in patients with impaired renal function undergoing coronary angiography and interventions.
Ramesh N; Pillai RK; Abraham T; Padmaja NP; Hameed S; Vijayaraghavan G
J Assoc Physicians India; 2006 Jun; 54():449-52. PubMed ID: 16909692
[TBL] [Abstract][Full Text] [Related]
5. Ascorbic acid prevents contrast-mediated nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention.
Spargias K; Alexopoulos E; Kyrzopoulos S; Iokovis P; Greenwood DC; Manginas A; Voudris V; Pavlides G; Buller CE; Kremastinos D; Cokkinos DV
Circulation; 2004 Nov; 110(18):2837-42. PubMed ID: 15492300
[TBL] [Abstract][Full Text] [Related]
6. Abbreviated dosing of N-acetylcysteine prevents contrast-induced nephropathy after elective and urgent coronary angiography and intervention.
Ochoa A; Pellizzon G; Addala S; Grines C; Isayenko Y; Boura J; Rempinski D; O'Neill W; Kahn J
J Interv Cardiol; 2004 Jun; 17(3):159-65. PubMed ID: 15209578
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of ascorbic acid, N-acetylcysteine, or combination of both on top of saline hydration versus saline hydration alone on prevention of contrast-Induced nephropathy: a prospective randomized study.
Albabtain MA; Almasood A; Alshurafah H; Alamri H; Tamim H
J Interv Cardiol; 2013 Feb; 26(1):90-6. PubMed ID: 22994682
[TBL] [Abstract][Full Text] [Related]
8. N-acetylcysteine and/or ascorbic acid versus placebo to prevent contrast-induced nephropathy in patients undergoing elective cardiac catheterization: The NAPCIN trial; A single-center, prospective, randomized trial.
Habib M; Hillis A; Hammad A
Saudi J Kidney Dis Transpl; 2016 Jan; 27(1):55-61. PubMed ID: 26787567
[TBL] [Abstract][Full Text] [Related]
9. Sodium bicarbonate versus saline for the prevention of contrast-induced nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention.
Maioli M; Toso A; Leoncini M; Gallopin M; Tedeschi D; Micheletti C; Bellandi F
J Am Coll Cardiol; 2008 Aug; 52(8):599-604. PubMed ID: 18702961
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of N-acetylcysteine and hydration versus placebo and hydration in decreasing contrast-induced renal dysfunction in patients undergoing coronary angiography with or without concomitant percutaneous coronary intervention.
Seyon RA; Jensen LA; Ferguson IA; Williams RG
Heart Lung; 2007; 36(3):195-204. PubMed ID: 17509426
[TBL] [Abstract][Full Text] [Related]
11. Preventive strategies of renal insufficiency in patients with diabetes undergoing intervention or arteriography (the PREVENT Trial).
Lee SW; Kim WJ; Kim YH; Park SW; Park DW; Yun SC; Lee JY; Kang SJ; Lee CW; Lee JH; Choi SW; Seong IW; Suh J; Cho YH; Lee NH; Cheong SS; Yoo SY; Lee BK; Lee SG; Hyon MS; Shin WY; Lee SW; Jang JS; Park SJ
Am J Cardiol; 2011 May; 107(10):1447-52. PubMed ID: 21420063
[TBL] [Abstract][Full Text] [Related]
12. Impact of high-dose N-acetylcysteine versus placebo on contrast-induced nephropathy and myocardial reperfusion injury in unselected patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. The LIPSIA-N-ACC (Prospective, Single-Blind, Placebo-Controlled, Randomized Leipzig Immediate PercutaneouS Coronary Intervention Acute Myocardial Infarction N-ACC) Trial.
Thiele H; Hildebrand L; Schirdewahn C; Eitel I; Adams V; Fuernau G; Erbs S; Linke A; Diederich KW; Nowak M; Desch S; Gutberlet M; Schuler G
J Am Coll Cardiol; 2010 May; 55(20):2201-9. PubMed ID: 20466200
[TBL] [Abstract][Full Text] [Related]
13. Protection of radiocontrast induced nephropathy by vitamin E (alpha tocopherol): a randomized controlled pilot study.
Tasanarong A; Piyayotai D; Thitiarchakul S
J Med Assoc Thai; 2009 Oct; 92(10):1273-81. PubMed ID: 19845233
[TBL] [Abstract][Full Text] [Related]
14. Effect of N-acetylcysteine on cystatin C-based renal function after elective coronary angiography (ENABLE Study): a prospective, randomized trial.
Kim BJ; Sung KC; Kim BS; Kang JH; Lee KB; Kim H; Lee MH
Int J Cardiol; 2010 Feb; 138(3):239-45. PubMed ID: 18793808
[TBL] [Abstract][Full Text] [Related]
15. Prospective randomized study of N-acetylcysteine, fenoldopam, and saline for prevention of radiocontrast-induced nephropathy.
Allaqaband S; Tumuluri R; Malik AM; Gupta A; Volkert P; Shalev Y; Bajwa TK
Catheter Cardiovasc Interv; 2002 Nov; 57(3):279-83. PubMed ID: 12410497
[TBL] [Abstract][Full Text] [Related]
16. Acetylcysteine In Diabetes (AID): a randomized study of acetylcysteine for the prevention of contrast nephropathy in diabetics.
Coyle LC; Rodriguez A; Jeschke RE; Simon-Lee A; Abbott KC; Taylor AJ
Am Heart J; 2006 May; 151(5):1032.e9-12. PubMed ID: 16644332
[TBL] [Abstract][Full Text] [Related]
17. N-acetylcysteine and sodium bicarbonate versus N-acetylcysteine and standard hydration for the prevention of radiocontrast-induced nephropathy following coronary angiography.
Schmidt P; Pang D; Nykamp D; Knowlton G; Jia H
Ann Pharmacother; 2007 Jan; 41(1):46-50. PubMed ID: 17190844
[TBL] [Abstract][Full Text] [Related]
18. Ascorbic Acid for the prevention of contrast-induced nephropathy after coronary angiography in patients with chronic renal impairment: a randomized controlled trial.
Dvoršak B; Kanič V; Ekart R; Bevc S; Hojs R
Ther Apher Dial; 2013 Aug; 17(4):384-90. PubMed ID: 23931876
[TBL] [Abstract][Full Text] [Related]
19. Prophylaxis of contrast-induced nephropathy in patients undergoing coronary angiography.
MacNeill BD; Harding SA; Bazari H; Patton KK; Colon-Hernadez P; DeJoseph D; Jang IK
Catheter Cardiovasc Interv; 2003 Dec; 60(4):458-61. PubMed ID: 14624421
[TBL] [Abstract][Full Text] [Related]
20. Comparison of N-acetylcysteine and fenoldopam for preventing contrast-induced nephropathy (CAFCIN).
Ng TM; Shurmur SW; Silver M; Nissen LR; O'Leary EL; Rigmaiden RS; Cieciorka M; Porter LL; Ineck BA; Kline ME; Puumala SE
Int J Cardiol; 2006 May; 109(3):322-8. PubMed ID: 16039733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]